Lymphomas arising or relapsing in the central nervous system (CNS) have a dismal prognosis [1]. Very few active drugs passing through the blood brain barrier are available. Lenalidomide is a novel and extremely active compound in relapsed diffuse-large-B-cell-lymphoma (DLBCL) and mantle cell lymphoma (MCL) [2,3]. The pleiotropic action of Lenalidomide needs to be further exploited in different clinical settings and in combination with other drugs [4,5]. Thus far, patients with aggressive lymphomas and CNS involvement have been excluded from clinical trials and there are no data about Lenalidomide penetration in the CNS. Very recently, it was reported that Lenalidomide induced remission in a case of DLBCL relapsed within the CNS [6]. Here, we refer on a case of blastoid MCL [7] relapsed within the orbit and the CNS. The patient failed chemotherapy but achieved remission on Lenalidomide therapy. Furthermore, the presence of the drug was ascertained in the blood and in the cerebrospinal fluid (CSF) using an LC-MS/MS system consisting of a quadrupole mass spectrometer.

Lenalidomide for aggressive B-cell lymphoma involving the central nervous system? / Maria Christina, Cox; Mannino, Giuseppe; Luana, Lionetto; Naso, Virginia; Simmaco, Maurizio; ALOE SPIRITI, Maria Antonietta. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 86:11(2011), pp. 957-957. [10.1002/ajh.22148]

Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?

MANNINO, Giuseppe;NASO, VIRGINIA;SIMMACO, Maurizio;ALOE SPIRITI, Maria Antonietta
2011

Abstract

Lymphomas arising or relapsing in the central nervous system (CNS) have a dismal prognosis [1]. Very few active drugs passing through the blood brain barrier are available. Lenalidomide is a novel and extremely active compound in relapsed diffuse-large-B-cell-lymphoma (DLBCL) and mantle cell lymphoma (MCL) [2,3]. The pleiotropic action of Lenalidomide needs to be further exploited in different clinical settings and in combination with other drugs [4,5]. Thus far, patients with aggressive lymphomas and CNS involvement have been excluded from clinical trials and there are no data about Lenalidomide penetration in the CNS. Very recently, it was reported that Lenalidomide induced remission in a case of DLBCL relapsed within the CNS [6]. Here, we refer on a case of blastoid MCL [7] relapsed within the orbit and the CNS. The patient failed chemotherapy but achieved remission on Lenalidomide therapy. Furthermore, the presence of the drug was ascertained in the blood and in the cerebrospinal fluid (CSF) using an LC-MS/MS system consisting of a quadrupole mass spectrometer.
2011
01 Pubblicazione su rivista::01a Articolo in rivista
Lenalidomide for aggressive B-cell lymphoma involving the central nervous system? / Maria Christina, Cox; Mannino, Giuseppe; Luana, Lionetto; Naso, Virginia; Simmaco, Maurizio; ALOE SPIRITI, Maria Antonietta. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 86:11(2011), pp. 957-957. [10.1002/ajh.22148]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/434016
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact